Xbrane And Stada’s Ranibizumab Snapped Up In North America

Bausch + Lomb Licenses Biosimilar Lucentis Rival For US And Canada

 
• By David Wallace
  
Eye
Eye care specialist Bausch + Lomb has struck a deal for Xbrane and Stada’s Ranibizumab • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products